Medications hub · Editorial overview
UK-licensed GLP-1 weight-management medicines
This is an editorial overview of the GLP-1 receptor agonists that hold UK MHRA marketing authorisation for chronic weight management. Each medicine is a Prescription Only Medicine. PeptideClear does not prescribe, dispense, or sell medication and does not recommend a specific medicine for a specific person. Whether any of these medicines is appropriate, and the dosing and monitoring used, are decisions for a UK-registered prescriber under the MHRA-approved Summary of Product Characteristics and Patient Information Leaflet.
tirzepatide
Tirzepatide (Mounjaro)
Eli Lilly · Once-weekly subcutaneous (per SmPC)
UK MHRA: type 2 diabetes (2022); chronic weight management (2024); OSA indication recognised 2026
Dual GIP and GLP-1 receptor agonist. Subject to NICE Technology Appraisal TA1026 for NHS weight-management use, with phased cohort rollout.
Read regulatory reference →
semaglutide
Semaglutide (Wegovy)
Novo Nordisk · Once-weekly subcutaneous (per SmPC)
UK MHRA: chronic weight management (2022); cardiovascular outcomes indication added April 2026
GLP-1 receptor agonist. SELECT trial supported the addition of a cardiovascular outcomes indication. NHS use governed by NICE TA875.
Read regulatory reference →
liraglutide
Liraglutide (Saxenda)
Novo Nordisk · Daily subcutaneous (per SmPC)
UK MHRA: chronic weight management (2017)
GLP-1 receptor agonist. Longest published UK paediatric evidence base in the class. NHS use historically governed by NICE TA664.
Read regulatory reference →
Editorial scope and limits
Each medicine reference page summarises the regulatory profile, mechanism (per SmPC), the published clinical trial programme, and the UK access framework (NHS pathway under NICE technology appraisals, alongside CQC-registered private clinics and MHRA-licensed pharmacies). The pages do not contain dosing schedules, side-effect triage, switching protocols, missed-dose runbooks, or eligibility decision tools. Those determinations sit with a UK-registered prescriber under the authoritative MHRA-approved product information.
We do not present comparison rankings between branded POMs. UK advertising rules restrict the comparison of named prescription medicines to the public. Where relative regulatory history matters (for example, the order in which UK MHRA marketing authorisations were granted, or the order in which NICE technology appraisals were issued) we report that as factual context.
Related editorial reference
- · NHS GLP-1 access · NICE TA1026 cohort framework
- · Aftercare and maintenance commentary
- · Protein intake on GLP-1 therapy
- · GLP-1 face: editorial overview
- · Perimenopause and GLP-1 commentary
- · PCOS and GLP-1 commentary
- · CQC-registered UK clinics directory
- · UK MHRA-licensed pharmacies directory
PeptideClear is editorial. We do not prescribe, dispense, or sell prescription medication. The MHRA-approved Summary of Product Characteristics and Patient Information Leaflet for each medicine, published on emc.medicines.org.uk, are authoritative. Your UK-registered prescriber decides whether a medicine is appropriate and how it should be used.